{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T16:55:23Z","timestamp":1772729723676,"version":"3.50.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,5,18]],"date-time":"2022-05-18T00:00:00Z","timestamp":1652832000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,5,18]],"date-time":"2022-05-18T00:00:00Z","timestamp":1652832000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Neutrophil gelatinase-associated lipocalin (NGAL) is expressed in atherosclerotic plaques and implicated in the development of cardiovascular diseases<jats:italic>.<\/jats:italic> Peripheral arterial disease (PAD) is an atherosclerotic disease that often results in major cardiovascular events. This study aimed to prospectively examine the potential of urine NGAL (uNGAL) in predicting worsening PAD status and major adverse limb events (MALE). Baseline urine NGAL (uNGAL) and urine creatinine (uCr) concentrations were measured in PAD (<jats:italic>n<\/jats:italic>\u2009=\u2009121) and non-PAD (<jats:italic>n<\/jats:italic>\u2009=\u200977)\u00a0patients. Levels of uNGAL were normalized for urine creatinine (uNGAL\/uCr). Outcomes included worsening PAD status, which was defined as a drop in ankle brachial index (ABI)\u2009&gt;\u20090.15, and major adverse limb events (MALE), which was defined as a need for surgical revascularization or amputations. PAD patients had 2.30-fold higher levels of uNGAL\/uCr [median (IQR) 31.8 (17.0\u201362.5) \u03bcg\/g] in comparison to non-PAD patients [median (IQR) 73.3 (37.5\u2013154.7) \u03bcg\/g] (<jats:italic>P<\/jats:italic>\u2009=\u20090.011). Multivariate cox analysis showed that uNGAL\/uCr levels were independently associated with predicting worsening PAD status and MALE outcomes. Cumulative survival analysis, over follow up period, demonstrated a direct correlation between elevated uNGAL\/uCr levels and PAD disease progression and MALE outcomes. These data demonstrate an association between elevated uNGAL\/uCr levels and worsening PAD disease status and MALE outcomes, indicating its potential for risk-stratification of PAD patients.<\/jats:p>","DOI":"10.1038\/s41598-022-12286-2","type":"journal-article","created":{"date-parts":[[2022,5,18]],"date-time":"2022-05-18T15:07:20Z","timestamp":1652886440000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Urinary neutrophil gelatinase-associated lipocalin (NGAL) can potentially predict vascular complications and reliably risk stratify patients with peripheral arterial disease"],"prefix":"10.1038","volume":"12","author":[{"given":"Mehroz","family":"Ehsan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muzammil H.","family":"Syed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdelrahman","family":"Zamzam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niousha","family":"Jahanpour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krishna K.","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rawand","family":"Abdin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad","family":"Qadura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,5,18]]},"reference":[{"key":"12286_CR1","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.hlc.2017.10.014","volume":"27","author":"SM Conte","year":"2018","unstructured":"Conte, S. M. & Vale, P. R. Peripheral arterial disease. Heart Lung Circ. 27, 427\u2013432 (2018).","journal-title":"Heart Lung Circ."},{"key":"12286_CR2","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1016\/S0140-6736(13)61249-0","volume":"382","author":"FGR Fowkes","year":"2013","unstructured":"Fowkes, F. G. R. et al. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis. Lancet 382, 1329\u20131340 (2013).","journal-title":"Lancet"},{"key":"12286_CR3","doi-asserted-by":"publisher","first-page":"e0186220","DOI":"10.1371\/journal.pone.0186220","volume":"12","author":"V Cornejo Del R\u00edo","year":"2017","unstructured":"Cornejo Del R\u00edo, V. et al. Prevalence of peripheral artery disease (PAD) and factors associated: an epidemiological analysis from the population-based Screening PRE-diabetes and type 2 DIAbetes (SPREDIA-2) study. PLoS ONE 12, e0186220 (2017).","journal-title":"PLoS ONE"},{"key":"12286_CR4","doi-asserted-by":"publisher","first-page":"2484","DOI":"10.1161\/CIRCULATIONAHA.107.736108","volume":"117","author":"MM McDermott","year":"2008","unstructured":"McDermott, M. M. et al. Asymptomatic peripheral arterial disease is associated with more adverse lower extremity characteristics than intermittent claudication. Circulation 117, 2484 (2008).","journal-title":"Circulation"},{"key":"12286_CR5","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1161\/CIRCULATIONAHA.112.108787","volume":"126","author":"S Subherwal","year":"2012","unstructured":"Subherwal, S. et al. Missed opportunities: despite improvement in use of cardioprotective medications among patients with lower-extremity peripheral artery disease, underuse remains. Circulation 126, 1345\u20131354 (2012).","journal-title":"Circulation"},{"key":"12286_CR6","doi-asserted-by":"publisher","first-page":"1976","DOI":"10.1001\/jama.2017.4150","volume":"317","author":"GA Roth","year":"2017","unstructured":"Roth, G. A. et al. Trends and patterns of geographic variation in cardiovascular mortality among US counties, 1980\u20132014. JAMA 317, 1976\u20131992 (2017).","journal-title":"JAMA"},{"key":"12286_CR7","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1161\/CIRCULATIONAHA.109.865600","volume":"120","author":"C Diehm","year":"2009","unstructured":"Diehm, C. et al. Mortality and vascular morbidity in older adults with asymptomatic versus symptomatic peripheral artery disease. Circulation 120, 2053\u20132061 (2009).","journal-title":"Circulation"},{"key":"12286_CR8","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1093\/eurheartj\/ehx095","volume":"39","author":"V Aboyans","year":"2018","unstructured":"Aboyans, V. et al. ESC guidelines on the diagnosis and treatment of peripheral arterial diseases, in collaboration with the European Society for Vascular Surgery (ESVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteriesEndorsed by: the European Stroke Organization (ESO)The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vasc. Eur. Heart J. 39, 763\u2013816 (2018).","journal-title":"Eur. Heart J."},{"key":"12286_CR9","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/j.jvs.2014.03.290","volume":"60","author":"MR Nehler","year":"2014","unstructured":"Nehler, M. R. et al. Epidemiology of peripheral arterial disease and critical limb ischemia in an insured national population. J. Vasc. Surg. 60, 686\u2013695 (2014).","journal-title":"J. Vasc. Surg."},{"key":"12286_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13047-019-0351-0","volume":"12","author":"A Mizzi","year":"2019","unstructured":"Mizzi, A., Cassar, K., Bowen, C. & Formosa, C. The progression rate of peripheral arterial disease in patients with intermittent claudication: a systematic review. J. Foot Ankle Res. 12, 1\u20139 (2019).","journal-title":"J. Foot Ankle Res."},{"key":"12286_CR11","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.ejvs.2015.10.022","volume":"51","author":"B Sigvant","year":"2016","unstructured":"Sigvant, B., Lundin, F. & Wahlberg, E. The risk of disease progression in peripheral arterial disease is higher than expected: a meta-analysis of mortality and disease progression in peripheral arterial disease. Eur. J. Vasc. Endovasc. Surg. 51, 395\u2013403 (2016).","journal-title":"Eur. J. Vasc. Endovasc. Surg."},{"key":"12286_CR12","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1053\/j.tvir.2016.04.001","volume":"19","author":"A Dua","year":"2016","unstructured":"Dua, A. & Lee, C. J. Epidemiology of peripheral arterial disease and critical limb ischemia. Tech. Vasc. Interv. Radiol. 19, 91\u201395 (2016).","journal-title":"Tech. Vasc. Interv. Radiol."},{"key":"12286_CR13","doi-asserted-by":"publisher","first-page":"3503","DOI":"10.1182\/blood.V89.10.3503","volume":"89","author":"N Borregaard","year":"1997","unstructured":"Borregaard, N. & Cowland, J. B. Granules of the human neutrophilic polymorphonuclear leukocyte. Blood 89, 3503\u20133521 (1997).","journal-title":"Blood"},{"key":"12286_CR14","doi-asserted-by":"publisher","first-page":"2229","DOI":"10.2215\/CJN.00980110","volume":"5","author":"L Cai","year":"2010","unstructured":"Cai, L., Rubin, J., Han, W., Venge, P. & Xu, S. The origin of multiple molecular forms in urine of HNL\/NGAL. Clin. J. Am. Soc. Nephrol. 5, 2229\u20132235 (2010).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"12286_CR15","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1053\/j.ajkd.2009.07.020","volume":"54","author":"M Haase","year":"2009","unstructured":"Haase, M. et al. Accuracy of neutrophil gelatinase-associated lipocalin (NGAL) in diagnosis and prognosis in acute kidney injury: a systematic review and meta-analysis. Am. J. Kidney Dis. 54, 1012\u20131024 (2009).","journal-title":"Am. J. Kidney Dis."},{"key":"12286_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/cc11855","volume":"17","author":"PB Hjortrup","year":"2013","unstructured":"Hjortrup, P. B., Haase, N., Wetterslev, M. & Perner, A. Clinical review: Predictive value of neutrophil gelatinase-associated lipocalin for acute kidney injury in intensive care patients. Crit. Care 17, 1\u201311 (2013).","journal-title":"Crit. Care"},{"key":"12286_CR17","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1002\/bit.20535","volume":"91","author":"A Jayaraman","year":"2005","unstructured":"Jayaraman, A. et al. Identification of neutrophil gelatinase-associated lipocalin (NGAL) as a discriminatory marker of the hepatocyte-secreted protein response to IL-1beta: a proteomic analysis. Biotechnol. Bioeng. 91, 502\u2013515 (2005).","journal-title":"Biotechnol. Bioeng."},{"key":"12286_CR18","doi-asserted-by":"publisher","first-page":"22565","DOI":"10.1074\/jbc.270.38.22565","volume":"270","author":"Q Liu","year":"1995","unstructured":"Liu, Q. & Nilsen-Hamilton, M. Identification of a new acute phase protein. J. Biol. Chem. 270, 22565\u201322570 (1995).","journal-title":"J. Biol. Chem."},{"key":"12286_CR19","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1111\/j.1365-2362.2010.02258.x","volume":"40","author":"D Bolignano","year":"2010","unstructured":"Bolignano, D., Coppolino, G., Lacquaniti, A. & Buemi, M. From kidney to cardiovascular diseases: NGAL as a biomarker beyond the confines of nephrology. Eur. J. Clin. Invest. 40, 273\u2013276 (2010).","journal-title":"Eur. J. Clin. Invest."},{"key":"12286_CR20","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1161\/01.ATV.0000193567.88685.f4","volume":"26","author":"AL Hemdahl","year":"2006","unstructured":"Hemdahl, A. L. et al. Expression of neutrophil gelatinase-associated lipocalin in atherosclerosis and myocardial infarction. Arterioscler. Thromb. Vasc. Biol. 26, 136\u2013142 (2006).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"12286_CR21","doi-asserted-by":"publisher","first-page":"e0137924","DOI":"10.1371\/journal.pone.0137924","volume":"10","author":"R Oberoi","year":"2015","unstructured":"Oberoi, R. et al. Lipocalin (LCN) 2 mediates pro-atherosclerotic processes and is elevated in patients with coronary artery disease. PLoS ONE 10, e0137924 (2015).","journal-title":"PLoS ONE"},{"key":"12286_CR22","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1373\/clinchem.2006.075614","volume":"53","author":"Y Wang","year":"2007","unstructured":"Wang, Y. et al. Lipocalin-2 is an inflammatory marker closely associated with obesity, insulin resistance, and hyperglycemia in humans. Clin. Chem. 53, 34\u201341 (2007).","journal-title":"Clin. Chem."},{"key":"12286_CR23","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/j.ejvs.2016.01.009","volume":"51","author":"W Eilenberg","year":"2016","unstructured":"Eilenberg, W. et al. Neutrophil gelatinase-associated lipocalin (NGAL) is associated with symptomatic carotid atherosclerosis and drives pro-inflammatory state in vitro. Eur. J. Vasc. Endovasc. Surg. 51, 623\u2013631 (2016).","journal-title":"Eur. J. Vasc. Endovasc. Surg."},{"key":"12286_CR24","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.jacc.2012.04.017","volume":"60","author":"S Lindberg","year":"2012","unstructured":"Lindberg, S. et al. Prognostic utility of neutrophil gelatinase-associated lipocalin in predicting mortality and cardiovascular events in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention. J. Am. Coll. Cardiol. 60, 339\u2013345 (2012).","journal-title":"J. Am. Coll. Cardiol."},{"key":"12286_CR25","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1159\/000365200","volume":"4","author":"K Soylu","year":"2014","unstructured":"Soylu, K. et al. Serum neutrophil gelatinase-associated lipocalin levels and aortic stiffness in noncritical coronary artery disease. Cardiorenal. Med. 4, 147\u2013154 (2014).","journal-title":"Cardiorenal. Med."},{"key":"12286_CR26","doi-asserted-by":"publisher","first-page":"37258","DOI":"10.1074\/jbc.M106089200","volume":"276","author":"L Yan","year":"2001","unstructured":"Yan, L., Borregaard, N., Kjeldsen, L. & Moses, M. A. The high molecular weight urinary matrix metalloproteinase (MMP) activity is a complex of gelatinase B\/MMP-9 and neutrophil gelatinase-associated lipocalin (NGAL). Modulation of MMP-9 activity by NGAL. J. Biol. Chem. 276, 37258\u201337265 (2001).","journal-title":"J. Biol. Chem."},{"key":"12286_CR27","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.amjcard.2015.03.043","volume":"116","author":"A Palazzuoli","year":"2015","unstructured":"Palazzuoli, A. et al. Comparison of neutrophil gelatinase-associated lipocalin versus B-type natriuretic peptide and cystatin C to predict early acute kidney injury and outcome in patients with acute heart failure. Am. J. Cardiol. 116, 104\u2013111 (2015).","journal-title":"Am. J. Cardiol."},{"key":"12286_CR28","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.ijcard.2011.07.080","volume":"165","author":"M Alvelos","year":"2013","unstructured":"Alvelos, M. et al. Prognostic value of neutrophil gelatinase-associated lipocalin in acute heart failure. Int. J. Cardiol. 165, 51\u201355 (2013).","journal-title":"Int. J. Cardiol."},{"key":"12286_CR29","doi-asserted-by":"publisher","first-page":"e004582","DOI":"10.1161\/JAHA.116.004582","volume":"6","author":"Y Nakada","year":"2017","unstructured":"Nakada, Y. et al. Prognostic value of urinary neutrophil gelatinase-associated lipocalin on the first day of admission for adverse events in patients with acute decompensated heart failure. J. Am. Heart Assoc. Cardiovasc. Cerebrovasc. Dis. 6, e004582 (2017).","journal-title":"J. Am. Heart Assoc. Cardiovasc. Cerebrovasc. Dis."},{"key":"12286_CR30","first-page":"1","volume":"2020","author":"T Li","year":"2020","unstructured":"Li, T. et al. The role of matrix metalloproteinase-9 in atherosclerotic plaque instability. Med. Inflamm. 2020, 1\u201313 (2020).","journal-title":"Med. Inflamm."},{"key":"12286_CR31","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1111\/j.1365-2796.2004.01431.x","volume":"257","author":"MH Tayebjee","year":"2005","unstructured":"Tayebjee, M. H., Tan, K. T., MacFadyen, R. J. & Lip, G. Y. H. Abnormal circulating levels of metalloprotease 9 and its tissue inhibitor 1 in angiographically proven peripheral arterial disease: relationship to disease severity. J. Intern. Med. 257, 110\u2013116 (2005).","journal-title":"J. Intern. Med."},{"key":"12286_CR32","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1056\/NEJMoa2000052","volume":"382","author":"MP Bonaca","year":"2020","unstructured":"Bonaca, M. P. et al. Rivaroxaban in peripheral artery disease after revascularization. N. Engl. J. Med. 382, 1994\u20132004 (2020).","journal-title":"N. Engl. J. Med."},{"key":"12286_CR33","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1016\/j.jacc.2019.11.057","volume":"75","author":"A Haine","year":"2020","unstructured":"Haine, A. et al. Sex-specific risks of major cardiovascular and limb events in patients with symptomatic peripheral artery disease. J. Am. Coll. Cardiol. 75, 608\u2013617 (2020).","journal-title":"J. Am. Coll. Cardiol."},{"key":"12286_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-021-90395-0","volume":"11","author":"A Zamzam","year":"2021","unstructured":"Zamzam, A. et al. Urinary fatty acid binding protein 3 (uFABP3) is a potential biomarker for peripheral arterial disease. Sci. Rep. 11, 1\u20136 (2021).","journal-title":"Sci. Rep."},{"key":"12286_CR35","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.jvssci.2020.08.003","volume":"1","author":"MH Syed","year":"2020","unstructured":"Syed, M. H. et al. Fatty acid binding protein 3 is associated with peripheral arterial disease. JVS Vasc. Sci. 1, 168\u2013175 (2020).","journal-title":"JVS Vasc. Sci."},{"key":"12286_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/jcm9092843","volume":"9","author":"A Zamzam","year":"2020","unstructured":"Zamzam, A. et al. Fatty acid binding protein 4-A circulating protein associated with peripheral arterial disease in diabetic patients. J. Clin. Med. 9, 1\u20138 (2020).","journal-title":"J. Clin. Med."},{"key":"12286_CR37","doi-asserted-by":"crossref","unstructured":"Conte, M. S. et al. Society for vascular surgery practice guidelines for atherosclerotic occlusive disease of the lower extremities: management of asymptomatic disease and claudication. J. Vasc. Surg. 61, 2S-41S.e1 (2015).","DOI":"10.1016\/j.jvs.2014.12.009"},{"key":"12286_CR38","doi-asserted-by":"publisher","first-page":"2890","DOI":"10.1161\/CIR.0b013e318276fbcb","volume":"126","author":"V Aboyans","year":"2012","unstructured":"Aboyans, V. et al. Measurement and interpretation of the Ankle-Brachial Index: a scientific statement from the American Heart Association. Circulation 126, 2890\u20132909 (2012).","journal-title":"Circulation"},{"key":"12286_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1024\/0301-1526\/a000834","volume":"48","author":"F Ulrich","year":"2019","unstructured":"Ulrich, F. et al. ESVM Guideline on peripheral arterial disease. VASA Zeitschrift fur Gefasskrankheiten 48, 1\u201380 (2019).","journal-title":"VASA Zeitschrift fur Gefasskrankheiten"},{"key":"12286_CR40","doi-asserted-by":"publisher","first-page":"101","DOI":"10.2174\/157340308784245810","volume":"4","author":"TH Khan","year":"2008","unstructured":"Khan, T. H., Farooqui, F. A. & Niazi, K. Critical review of the ankle brachial index. Curr. Cardiol. Rev. 4, 101 (2008).","journal-title":"Curr. Cardiol. Rev."},{"key":"12286_CR41","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/j.jvs.2016.02.066","volume":"64","author":"CL Wassel","year":"2016","unstructured":"Wassel, C. L. et al. Ankle brachial index (ABI) predicts change over time in functional status in the San Diego population study (SDPS). J. Vasc. Surg. 64, 656 (2016).","journal-title":"J. Vasc. Surg."},{"key":"12286_CR42","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-15603-3_7","author":"KN McClary","year":"2022","unstructured":"McClary, K. N. & Massey, P. Ankle brachial index. Assess. Preclin. Organ Damage Hypertens. https:\/\/doi.org\/10.1007\/978-3-319-15603-3_7 (2022).","journal-title":"Assess. Preclin. Organ Damage Hypertens."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-12286-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-12286-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-12286-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T02:58:39Z","timestamp":1669345119000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-12286-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,18]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["12286"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-12286-2","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,18]]},"assertion":[{"value":"3 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"8312"}}